Antiemesis: Clinical practice guidelines in Oncology™

David S. Ettinger, Philip J. Bierman, Bob Bradbury, Carli C. Comish, Georgiana Ellis, Robert J. Ignoffo, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Michael Anne Markiewicz, Robert McNulty, Lidia Nabati, Barbara Todaro, Susan Urba, Sally Yowell

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.

Original languageEnglish (US)
Pages (from-to)12-33
Number of pages22
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number1
StatePublished - Jan 1 2007

Keywords

  • 5-HT3 receptor antagonists
  • Anticipatory emesis
  • Antiemesis
  • Aprepitant
  • Chemotherapy-induced emesis
  • NCCN Clinical Practice Guidelines
  • NK-1-receptor antagonists
  • Nausea and vomiting
  • Palonosetron
  • Radiation-induced emesis

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Antiemesis: Clinical practice guidelines in Oncology™'. Together they form a unique fingerprint.

  • Cite this

    Ettinger, D. S., Bierman, P. J., Bradbury, B., Comish, C. C., Ellis, G., Ignoffo, R. J., Kirkegaard, S., Kloth, D. D., Kris, M. G., Lim, D., Markiewicz, M. A., McNulty, R., Nabati, L., Todaro, B., Urba, S., & Yowell, S. (2007). Antiemesis: Clinical practice guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(1), 12-33.